BAO PHARMA-B(02659): The follow-up of phase III clinical trial for KJ103 in desensitization treatment for kidney transplantation has been completed.

BAO PHARMA-B (02659) announced that the Phase III clinical trial of KJ103, as a desensitization therapy for highly sensitive patients awaiting kidney transplantation in China, has completed all major trial follow-ups for enrolled subjects on March 20, 2026. The company will soon submit a new drug application to the National Medical Products Administration. KJ103 is a globally pioneering, low immunogenicity innovative recombinant immunoglobulin G ("IgG") degrading enzyme, used to treat various immune-mediated diseases and conditions driven by pathological IgG antibodies. In August 2025, the company initiated the Phase III clinical trial of KJ103 for desensitization treatment in highly sensitized kidney transplant patients (CTR20252973), aiming to effectively eliminate pre-existing HLA antibodies and prevent hyperacute rejection reactions. In November 2024, the company obtained breakthrough therapy designation for KJ103 in this indication from the National Medical Products Administration.